MX390435B - Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. - Google Patents
Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.Info
- Publication number
- MX390435B MX390435B MX2019004969A MX2019004969A MX390435B MX 390435 B MX390435 B MX 390435B MX 2019004969 A MX2019004969 A MX 2019004969A MX 2019004969 A MX2019004969 A MX 2019004969A MX 390435 B MX390435 B MX 390435B
- Authority
- MX
- Mexico
- Prior art keywords
- exon
- growth factor
- factor receptor
- epidermal growth
- selective inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe un agente antitumor que comprende un compuesto seleccionado del grupo que consiste de Compuestos A hasta D descritos en la especificación, o una sal de los mismos, para tratar un paciente con tumor maligno que expresa EGFR que tiene la mutación de inserción de exón 20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213072 | 2016-10-31 | ||
| PCT/JP2017/037186 WO2018079310A1 (ja) | 2016-10-31 | 2017-10-13 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019004969A MX2019004969A (es) | 2019-09-18 |
| MX390435B true MX390435B (es) | 2025-03-20 |
Family
ID=62024991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004969A MX390435B (es) | 2016-10-31 | 2017-10-13 | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11857513B2 (es) |
| EP (1) | EP3533449B1 (es) |
| JP (1) | JP6896755B2 (es) |
| KR (1) | KR102639585B1 (es) |
| CN (1) | CN110191711B (es) |
| AU (1) | AU2017350440B2 (es) |
| BR (1) | BR112019008374A2 (es) |
| DK (1) | DK3533449T3 (es) |
| ES (1) | ES2955832T3 (es) |
| FI (1) | FI3533449T3 (es) |
| HU (1) | HUE063712T2 (es) |
| IL (1) | IL266239B2 (es) |
| JO (1) | JOP20190073A1 (es) |
| MX (1) | MX390435B (es) |
| MY (1) | MY199395A (es) |
| NZ (1) | NZ752937A (es) |
| PH (1) | PH12019500957A1 (es) |
| PL (1) | PL3533449T3 (es) |
| PT (1) | PT3533449T (es) |
| SG (1) | SG11201903875QA (es) |
| TW (1) | TWI774699B (es) |
| WO (1) | WO2018079310A1 (es) |
| ZA (1) | ZA201902629B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FI3902548T3 (fi) * | 2018-12-28 | 2025-07-17 | Taiho Pharmaceutical Co Ltd | Hoitoresistentin L718- ja/tai L792-mutaation omaavan EGFR:n inhibiittori käytettäväksi syövän hoitamisessa |
| PH12021551957A1 (en) | 2019-02-15 | 2022-05-23 | Taiho Pharmaceutical Co Ltd | 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| CN116096372B (zh) * | 2020-07-09 | 2024-09-03 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202515577A (zh) * | 2023-06-27 | 2025-04-16 | 日商大鵬藥品工業股份有限公司 | 患有具有ｅｇｆｒ畸變的非小細胞肺癌之個體的治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| JP2008533172A (ja) | 2005-03-17 | 2008-08-21 | ノバルティス アクチエンゲゼルシャフト | チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| CA2767556C (en) | 2009-07-10 | 2017-11-28 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| TW201309668A (zh) | 2011-01-07 | 2013-03-01 | Taiho Pharmaceutical Co Ltd | 新穎雙環式化合物或其鹽 |
| US9145414B2 (en) | 2011-09-30 | 2015-09-29 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| MX351863B (es) | 2012-02-23 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. |
| TWI558706B (zh) | 2013-02-22 | 2016-11-21 | Taiho Pharmaceutical Co Ltd | A tricyclic compound and a tricyclic compound which can be produced by the production method |
| NO3037424T3 (es) | 2013-08-22 | 2018-04-07 | ||
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| ES2972895T3 (es) | 2017-09-01 | 2024-06-17 | Taiho Pharmaceutical Co Ltd | Inhibidor selectivo del EGFR mutante en el exón 18 y/o en el exón 21 |
-
2017
- 2017-06-16 JO JOP/2019/0073A patent/JOP20190073A1/ar unknown
- 2017-10-13 MY MYPI2019002386A patent/MY199395A/en unknown
- 2017-10-13 KR KR1020197015270A patent/KR102639585B1/ko active Active
- 2017-10-13 FI FIEP17864975.2T patent/FI3533449T3/fi active
- 2017-10-13 MX MX2019004969A patent/MX390435B/es unknown
- 2017-10-13 DK DK17864975.2T patent/DK3533449T3/da active
- 2017-10-13 CN CN201780067762.5A patent/CN110191711B/zh active Active
- 2017-10-13 SG SG11201903875QA patent/SG11201903875QA/en unknown
- 2017-10-13 PT PT178649752T patent/PT3533449T/pt unknown
- 2017-10-13 JP JP2018547565A patent/JP6896755B2/ja active Active
- 2017-10-13 NZ NZ752937A patent/NZ752937A/en unknown
- 2017-10-13 TW TW106135203A patent/TWI774699B/zh active
- 2017-10-13 ES ES17864975T patent/ES2955832T3/es active Active
- 2017-10-13 EP EP17864975.2A patent/EP3533449B1/en active Active
- 2017-10-13 HU HUE17864975A patent/HUE063712T2/hu unknown
- 2017-10-13 WO PCT/JP2017/037186 patent/WO2018079310A1/ja not_active Ceased
- 2017-10-13 BR BR112019008374A patent/BR112019008374A2/pt not_active Application Discontinuation
- 2017-10-13 AU AU2017350440A patent/AU2017350440B2/en active Active
- 2017-10-13 IL IL266239A patent/IL266239B2/en unknown
- 2017-10-13 PL PL17864975.2T patent/PL3533449T3/pl unknown
- 2017-10-31 US US16/345,792 patent/US11857513B2/en active Active
-
2019
- 2019-04-25 ZA ZA2019/02629A patent/ZA201902629B/en unknown
- 2019-04-29 PH PH12019500957A patent/PH12019500957A1/en unknown
-
2023
- 2023-11-17 US US18/512,528 patent/US20240148734A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390435B (es) | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| TN2017000486A1 (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| MY198004A (en) | Antitumoral compounds | |
| IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| WO2015143424A3 (en) | Methods of treating cancer | |
| JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
| MX2016014559A (es) | Compuestos para el tratamiento de cancer. | |
| MX2023000191A (es) | Metodos de fabricacion y uso de inhibidores de pde9. | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2018008507A (es) | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| EP3969001A4 (en) | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF NOTCH-ACTIVATED BREAST CANCER | |
| WO2015145388A3 (en) | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |